These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39004098)

  • 1. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis.
    Jenei K; Gentilini A; Haslam A; Prasad V
    Lancet Oncol; 2024 Aug; 25(8):979-988. PubMed ID: 39004098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis.
    Zosso-Pavic M; Li Q; Atiek E; Wolfer A; Rohr UP
    Lancet Oncol; 2024 Jun; 25(6):770-778. PubMed ID: 38754450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020.
    Pham C; Le K; Draves M; Seoane-Vazquez E
    JAMA Intern Med; 2023 Apr; 183(4):290-297. PubMed ID: 36780147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners.
    Hotaki LT; Shrestha A; Bennett MP; Valdes IL; Lee SH; Wang Y; Spillman D; MacAulay T; Hunt M; Gervais J; Mafi M; Panetta V; Looi YH; Shum M; Atiek E; Meincke R; Rohr UP; Ainbinder D; Boehm-Cagan A; Luxenburg O; Cerqueira MR; Mouawad LS; Thees MFRES; Prasad K; de Claro RA
    Ther Innov Regul Sci; 2023 Jul; 57(4):875-885. PubMed ID: 37072651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Project Orbis: Global Collaborative Review Program.
    de Claro RA; Spillman D; Hotaki LT; Shum M; Mouawad LS; Santos GML; Robinson K; Hunt M; Healy C; Chan A; Looi YH; Rodrigues C; Rohr UP; Walther C; Pazdur R
    Clin Cancer Res; 2020 Dec; 26(24):6412-6416. PubMed ID: 33037016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis.
    Ivama-Brummell AM; Marciniuk FL; Wagner AK; Osorio-de-Castro CGS; Vogler S; Mossialos E; Tavares-de-Andrade CL; Naci H
    Lancet Reg Health Am; 2023 Jun; 22():100506. PubMed ID: 37235087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
    Pinto A; Naci H; Neez E; Mossialos E
    Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.
    Lau C; Dranitsaris G
    Curr Oncol; 2022 Oct; 29(11):8031-8042. PubMed ID: 36354695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.
    Michaeli DT; Mills M; Kanavos P
    Appl Health Econ Health Policy; 2022 Sep; 20(5):757-768. PubMed ID: 35821360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
    Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN
    JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.
    Lythgoe MP; Krell J; Bower M; Murphy R; Marriott J; Blagden SP; Aggarwal A; Sullivan R
    Lancet Oncol; 2023 Apr; 24(4):e150-e160. PubMed ID: 36990613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.
    Miller JE; Mello MM; Wallach JD; Gudbranson EM; Bohlig B; Ross JS; Gross CP; Bach PB
    JAMA Netw Open; 2021 May; 4(5):e217075. PubMed ID: 33950209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appraisal of Novel Oncological Therapies by the Scottish Medicines Consortium and the National Institute for Health and Care Excellence: A Comparative Study of Six Years of Data.
    Taylor R
    Cureus; 2023 Dec; 15(12):e50560. PubMed ID: 38222244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.
    Gupta R; Dhruva SS; Fox ER; Ross JS
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1066-1076. PubMed ID: 28944731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment.
    Ho C; Lim HJ; Regier DA
    Curr Oncol; 2022 Jan; 29(2):402-410. PubMed ID: 35200536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.